KOLO MedTech's new funding round successfully indicated the company's potential and expectations from the public. With the new innovation being published, KOLO might lead the industry into a higher level.
On July 28, 2O22, KOLO MedTech Fund Ltd. (珂纳医疗科技) announced its completion of the Series B+ funding round. The funding amount of this round is approximately CNY 100 million. This funding round was led by Jiangsu Qianrong Capital Management, and followed by Walden International.
KOLO MedTech mentioned the use of the funding. It will quickly launch its self-developed high-frequency ultrasound imaging system to the global market. The funding will also be used to develop a new generation of CMUT chips and innovative ultrasound imaging products, with the help of the core patents of semiconductor ultrasound CMUT chips.
Established in 2013, KOLO MedTech has become the global leader in the CMUT chip technology. As the only company in the global industry that does not require a third-party IP licensing, KOLO MedTech is inevitably become the top choice for many experts in the industry. Its innovation is leading the industry into a higher and newer stage. Its products also created new standards for medical ultrasound imaging.
The company is also studying the development of other products. For example, the two-dimensional array ultrasound probe could be easily used for medical and research purposes. The three-dimensional ultrasound stereo imaging system is being developed to lower the baseline for users and create easier ways to use. If they successfully innovated these products, it will be a remarkable improvement in the industry.